Mobia Medical(NASDAQ) MOBI

Mobia Medical, Inc. helps stroke survivors regain hand and arm movement. It makes an implanted device to stimulate nerves during physical therapy. This technology helps patients regain independence long after a stroke.

Restoring Movement After Stroke

• Vivistim System: An implanted generator and lead that deliver nerve stimulation to improve motor function; accounts for 100% of revenue.
• Vivistim Therapy: A treatment process that uses stimulation during physical tasks to increase neuroplasticity.
• Commercial Support: Specialized teams that provide education and support to hospital staff during system adoption.

Expanding the Commercial Reach

• Completed an initial public offering in May 2026 with net proceeds of $134.0 million.
• Secured an elevated payment level from Medicare for implantation procedures starting Jan. 1, 2026.
• Published clinical data in July 2026 showing motor improvements sustained for at least two years.
• Increased commercial headcount in 2026 to target 1,500 primary and comprehensive stroke centers.

A Unique Regulatory Advantage

Mobia holds the only FDA approval for a device treating chronic ischemic stroke survivors with moderate to severe impairments. The company uses third-party contract manufacturers to scale production while limiting its own capital investment.

Checking the Financial Pulse

• Revenue was $25.6 million for the six-month period ended June 30, 2026, up 107.4% year over year.
• Net loss was $38.8 million for the six-month period ended June 30, 2026, up 83.4% year over year.
• Cash and cash equivalents reached $177.1 million as of June 30, 2026.
• Selling, general, and administrative expenses rose 85.1% year over year to $52.1 million for the six-month period ended June 30, 2026.
• Gross margin reached 82.8% for the six-month period ended June 30, 2026.

Bottom Line

Mobia has transitioned from a research-focused startup to a commercial healthcare company with a specialized stroke recovery device. Its growth depends on expanding hospital adoption and securing wider insurance coverage for its therapy.